Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urine Dosimetry for Flortaucipir
NCT02336360Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Total Integrated Radioactivity Excreted in Urine. Started Jan 2015; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02336360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336360.